

**Procter & Gamble – I.P. Division****IMPORTANT CONFIDENTIALITY NOTICE**

The documents accompanying this telecopy transmission contain confidential information belonging to the sender which is legally protected. The information is intended only for the use of the individual or entity named below. If you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution or the taking of any action in reliance on the contents of this telecopied information is strictly prohibited. If you have received this telecopy in error, please immediately notify us by telephone (collect) to arrange for return of the telecopied document to us.

**FACSIMILE TRANSMITTAL SHEET AND  
CERTIFICATE OF TRANSMISSION UNDER 37 CFR 1.8****RECEIVED  
CENTRAL FAX CENTER****MAR 19 2004****OFFICIAL****TO: EXAMINER R. DESAI United States Patent and Trademark Office**

Fax No. 703-872-9306

Phone No. 571-272-0684

*I hereby certify that this correspondence is being facsimile transmitted to the United States Patent and Trademark Office on March 19, 2004 to the above-identified facsimile number.*

*Linda S Jernigan* (Signature)

**FROM: Linda S Jernigan** Typed or printed name of person signing Certificate)

Fax No. 513-622-3300

Phone No. 513-622-2811

Listed below are the item(s) being submitted with  
This Certificate of Transmission:\*\*

Number of Pages Including This Page: 10  
Inventor(s): Degenhardt et al.

- 1) Reply – 9 pages
- 2)
- 3)

S.N. 09/996,657  
Filed: November 29, 2001  
Case: 8375D

Note: The Declaration conforms with our Letter of Change to the USPTO (Attorney Docket No. change) on January 28, 2004.

Appl. No. 09/996,657  
Atty. Docket No. 8375D  
Response dated March 19, 2004  
Reply to Office Action February 6, 2004  
Customer No. 27752

RECEIVED  
CENTRAL FAX CENTER

MAR 19 2004

OFFICIAL

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application No.	:	09/996,657
Applicant(s)	:	Degenhardt <i>et al.</i>
Filed	:	November 29, 2001
Title	:	SUBSTITUTED HETEROCYCLIC COMPOUNDS FOR TREATING MULTIDRUG RESISTANCE
TC/A.U.	:	1625
Examiner	:	R. Desai
Conf. No.	:	6277
Docket No.	:	8375D
Customer No.	:	27752

REPLY UNDER 37 CFR §1.111

Mail Stop Non-Fee Amendment  
Commissioner for Patents  
P. O. Box 1450  
Alexandria, VA 22313-1450

Dear Sir:

INTRODUCTORY REMARKS

In response to the Office Action of February 6, 2004, please consider the following amendments and remarks and reconsider the application.

Appl. No. 09/996,657  
Att. Docket No. 8375D  
Response dated March 19, 2004  
Reply to Office Action February 6, 2004  
Customer No. 27752

Please amend the above-identified application as follows:

*Amendments to the Specification* begin on page 3 of this paper

*Amendments to the Claims* begin on page 4 of this paper.

*Remarks* begin on page 7 of this paper.

*Replacement Abstract* begins on page 9 of this paper.